Shin Nippon Biomedical Laboratories Ltd – Lobbying Governance & Transparency

Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:

Lobbying Governance

Overall Assessment	Analysis	Score
Limited	Shin Nippon Biomedical Laboratories discloses a rudimentary process for checking that its policy-engagement activities match its climate strategy: it explains that "担当者が経済産業省、環境省などの官公庁が主催している気候変動関連セミナーなどに参加し、情報を収集しています" and that the information gathered is "整理した上で、適宜、環境委員会、SDGs委員会に報告し、必要に応じて当社グループの気候変動戦略に反映". This indicates that climate-related external engagement is at least reviewed by internal bodies (the Environment Committee and SDGs Committee), suggesting some oversight of how such engagement aligns with the company’s climate strategy. However, the disclosure does not identify any individual or board-level authority responsible for approving or monitoring lobbying positions, does not describe any systematic assessment of trade-association positions or other indirect lobbying, and the company admits "No, and we do not plan to have one in the next two years" when asked about committing to conduct engagement in line with the Paris Agreement. Overall, while there is a basic review mechanism, the company does not disclose a formal lobbying-governance framework, regular alignment reviews, or transparent criteria for managing either direct or indirect lobbying activities. View Sources	D

Overall Assessment

Analysis

Score

Limited

Shin Nippon Biomedical Laboratories discloses a rudimentary process for checking that its policy-engagement activities match its climate strategy: it explains that "担当者が経済産業省、環境省などの官公庁が主催している気候変動関連セミナーなどに参加し、情報を収集しています" and that the information gathered is "整理した上で、適宜、環境委員会、SDGs委員会に報告し、必要に応じて当社グループの気候変動戦略に反映". This indicates that climate-related external engagement is at least reviewed by internal bodies (the Environment Committee and SDGs Committee), suggesting some oversight of how such engagement aligns with the company’s climate strategy. However, the disclosure does not identify any individual or board-level authority responsible for approving or monitoring lobbying positions, does not describe any systematic assessment of trade-association positions or other indirect lobbying, and the company admits "No, and we do not plan to have one in the next two years" when asked about committing to conduct engagement in line with the Paris Agreement. Overall, while there is a basic review mechanism, the company does not disclose a formal lobbying-governance framework, regular alignment reviews, or transparent criteria for managing either direct or indirect lobbying activities.

View Sources

Lobbying Transparency

Overall Assessment	Analysis	Score
Moderate	Shin Nippon Biomedical Laboratories provides a reasonable degree of clarity on its climate-policy lobbying. It explicitly names the Japanese “温対法（地球温暖化対策の推進に関する法律）” and “省エネ法（エネルギーの使用の合理化等に関する法律）” as the regulations it engages on and links these to the broader requirement for “mandatory climate-related reporting,” giving readers a clear view of the specific legislation involved. The company explains that its main method is “direct dialogue with policymakers,” carried out with the regulatory bodies responsible for those two laws, so both the mechanism and the governmental targets are identified, although no other channels such as industry associations or public consultations are mentioned. On objectives, the disclosure states that it advocates the introduction of “annual CO2 emissions reporting,” seeks “reductions” in those emissions, and promotes “equitable carbon reporting,” indicating at least two concrete outcomes it wants the policies to deliver. Taken together, these elements show moderate transparency, with clear policy references and stated goals, but only limited detail on the variety of lobbying mechanisms used.	C